News

Pharmabiz7d
Faron Pharma’s bexmarilimab demonstrates immune-activating and drug-sensitizing potential in myeloid malignancies
Faron Pharma’s bexmarilimab demonstrates immune-activating and drug-sensitizing potential in myeloid malignancies: Turku, Finland Wednesday, May 28, 2025, 16:00 Hrs [IST] Faron ...
Frontiers7d
Inhibition of the Na + -glucose transporter SGLT2 reduces glucose uptake and IFNg release from activated human CD4 + T cells
Phlorizin (25 µmol/L) reduced glycolysis at 5.6 mmol/L glucose and IFNg levels at both 5.6 mmol/L and 16.7 mmol/L glucose. In contrast, empagliflozin (0.5 µmol/L) only decreased IFNg levels in 16.7 ...
eLife14d
Single-cell profiling of the lung immune cells of diabetes-tuberculosis comorbidity reveals reduced type-II interferon and elevated Th17 responses
2021). As expected, the authors found differences in the cellular composition of the DM mice with or without TB or TB-only mice, including reduced IFNg response, elevated Th17 cells, increased IL-16 ...
eLife22d
Thymic dendritic cell-derived IL-27p28 promotes the establishment of functional bias against IFN-γ production in newly generated CD4 + T cells through STAT1-related epigenetic ...
Naïve CD4 T cells in CD11c-Cre p28-floxed mice express highly elevated levels of proinflammatory IFNg and the transcription factor T-bet. This phenotype turned out to be imposed by thymic dendritic ...
ascopubs.org8d
T-cell exhaustion and pre-existing T-cell immunity in circulation as predictive biomarkers for immunotherapy in NSCLC patients.
Precision medicine research on chemo-immunotherapy combination treatment for locally advanced or metastatic non-small cell lung cancer based on deep plasma proteomics. Effect of fusobacterium ...
ascopubs.org8d
The prognostic and predictive value of the immunological gene signatures interferon gamma and TIDE for patients with liver metastases from uveal melanoma treated with isolated ...
Real-world impact of immunotherapy in metastatic uveal melanoma: A retrospective single-center study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
Le Lézard9d
Faron's Bexmarilimab Demonstrates Immune-Activating and Drug-Sensitizing Potential in Myeloid Malignancies
TURKU, FI / ACCESS Newswire / May 27, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - New preclinical data published in Scientific Reports confirms CLEVER-1 inhibition by Bexmarilimab increases ...
Faron Pharmaceuticals: Faron's Bexmarilimab Demonstrates Immune-Activating and Drug-Sensitizing Potential in Myeloid Malignancies
TURKU, FI / ACCESS Newswire / May 27, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - New preclinical data published in Scientific Reports confirms CLEVER-1 inhibition by Bexmarilimab increases a ...